MICRO LABS LTD
GenericsMICRO LABS LTD is a generic drug manufacturer focused on Cardiovascular, Neurology, Respiratory. Key products include LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE.
MICRO LABS LTD's Key Drugs
MICRO LABS LTD's core commercial portfolio centers on CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, DICLOFENAC SODIUM AND MISOPROSTOL, OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.
Gastrointestinal Disorder
Osteoarthritis
Hypertension
Type 2 Diabetes Mellitus
Hypertension
MICRO LABS LTD's Recent FDA Approvals
MICRO LABS LTD secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
MICRO LABS LTD's Therapeutic Areas
MICRO LABS LTD's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MICRO LABS LTD's Top Competitors
MICRO LABS LTD's closest competitors by therapeutic-area and drug-target overlap include LEDERLE, Pfizer, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MICRO LABS LTD Pipeline Snapshot
Active clinical trials for MICRO LABS LTD across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (7)
Discontinued (2)
Company Info
- First Approval
- 1988-02-05
- Latest
- 2026-06-23
- Applications
- 109